Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Nautilus Biotechnology, Inc. (NAUT : NSDQ)
 
 • Company Description   
Nautilus Biotechnology Inc. is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus Biotechnology Inc., formerly known as Arya Sciences Acquisition Corp III, is based in SEATTLE.

Number of Employees: 113

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.85 Daily Weekly Monthly
20 Day Moving Average: 283,612 shares
Shares Outstanding: 124.46 (millions)
Market Capitalization: $479.18 (millions)
Beta:
52 Week High: $11.69
52 Week Low: $3.13
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -2.53% 9.77%
12 Week -0.26% 9.64%
Year To Date -25.68% -9.19%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2701 EASTLAKE AVENUE EAST SEATTLE
-
SEATTLE,WA 98102
USA
ph: 206-333-2001
fax: -
investorrelations@nautilus.bio http://www.nautilus.bio
 
 • General Corporate Information   
Officers
Sujal Patel - Chief Executive Officer; President and Director
Anna Mowry - Chief Financial Officer
Michael Altman - Director
Melissa Epperly - Director
Parag Mallick - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 63909J108
SIC: 3826
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/09/22
Share - Related Items
Shares Outstanding: 124.46
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $479.18 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.17 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.66 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/09/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.37
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -15.57
12/31/21 - -17.71
09/30/21 - -
ROA
03/31/22 - -14.77
12/31/21 - -15.16
09/30/21 - -
Current Ratio
03/31/22 - 51.06
12/31/21 - 60.09
09/30/21 - 83.68
Quick Ratio
03/31/22 - 51.06
12/31/21 - 60.09
09/30/21 - 83.68
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 2.81
12/31/21 - 2.93
09/30/21 - 3.04
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©